

INDEX

Volume Eight January through December 1974

DRUG INTELLIGENCE AND CLINICAL PHARMACY

January	Pages	1 - 48		July	Pages 413 - 452
February	Pages	49 - 96		August	Pages 453 - 500
March	Pages	97 - 152		September	Pages 501 - 560
April	Pages	153 - 208		October	Pages 561 - 620
May	Pages	209 - 264		November	Pages 621 - 680
Omitted	Pages	265 - 364		December	Pages 681 - 740
June	Pages	365 - 412			

A

Aarane, See Cromolyn
 Acetazolamide, use in seizure disorders, 581
 Acetylsalicylic Acid, See Aspirin
 Achromycin, See Tetracycline
 Adriamycin, anticancer drug (ab) 409; cardiotoxicity (ab) 145; chemotherapy (ab) 409; in thyroid cancer (ab) 411
Adverse Drug Reactions
 adriamycin, cardiotoxicity (ab) 145
 alcohol, G.I. tract bleeding (ab) 447
 amoxicillin, 542
 anticoagulation therapy, ophthalmodynamometry (ab) 204
 anticonvulsants, oncogenic? (ab) 496
 aspirin (ab) 42, 694; hepatitis (ab) 205; use in myocardial infarction (ab) 496
 bibliography of publications, 487
 camphorated oil, 692
 carbenicillin, hemostatic defect (ab) 677
 cephalixin, nephrotoxicity (ab) 548
 cephalothin, intravenous administration (ab) 409; toxic paranoic reaction, 71
 cephalosporin, IV administration (ab) 409
 Chinese herb medications, agranulocytosis (ab) 676
 corticosteroids, filtering blebs after cataract extraction (ab) 495
 corticosteroids, neurological complications (ab) 253
 corticosteroids, uveitis (ab) 448
 cyclophosphamide, bladder toxicity (ab) 41
 demeclocycline (ab) 150; vasopressin-resistant diabetes insipidus (ab) 41
 detection, 656
 digoxin, frequency of digitoxicity (ab) 677; reduction of toxicity (ab) 495
 dimethyl sulfoxide, toxicity (letter) 558
 diphenylhydantoin, congenital malformations (ab) 204; hepatic necrosis (ab) 678; pure RBC aplasia (ab) 548
 doxycycline, photosensitivity (ab) 252
 drug-induced blood dyscrasias (ab) 203
 editorial, perspectives on, 571
 estrogen, massive hyperlipidemia (ab) 409
 ethambutol, ocular toxicity (ab) 253
 fetal and newborn, 690
 flucytosine, fatal aplastic anemia (ab) 676
 fluorinated steroids, topical use (ab) 548
 gastrointestinal manifestations (ab) 252
 gentamicin, 650
 glycerol, hemolysis, hemoglobinuria, renal failure (ab) 408
 heparin, disseminated intravascular coagulation (ab) 495
 heroin addiction (ab) 150
 hexachlorophene, poisoning & death (ab) 447
 insulin, hypoglycemia (ab) 447
 intralipid infusions (ab) 145
 intravenous pyelography, acute renal failure (ab) 548
 levodopa, dementia in Parkinsonism (ab) 92
 lincomycin, colitis (ab) 146
 LSD, carotid artery occlusion (ab) 495
 metallic mercury, enterocutaneous fistula from (ab) 495
 methicillin, 115; nephritis (ab) 677
 methotrexate (ab) 146; paraplegia (ab) 204
 methoxyflurane, hepatitis (ab) 494
 methylene blue, necrotic subcutaneous abscesses (ab) 677
 myasthenia gravis, 255
 nalidixic acid, intracranial hypertension and papilledema (ab) 204
 nicotinic acid, maculopathy (ab) 92
 nitrofurantoin, acute pneumonia, 16
 oral contraceptives, coagulation changes (ab) 675; cryptogenic cerebral embolism (ab) 205

oxacillin (ab) 150; - induced nephritis (ab) 447
 parenteral alimentation, paresthesias and hypophosphatemia (ab) 92
 pentazocine addiction, endocarditis & pulmonary embolism (ab) 252
 perspective (ed) 571
 phenothiazines, 166; induced reactions, physostigmine effects (ab) 252
 phenytoin, choreo-athetosis and encephalopathy (ab) 676
 physostigmine effects, phenothiazine-induced extrapyramidal reactions (ab) 252; physostigmine-amitriptyline overdose, 144
 potassium penicillin G, cardiac arrest (ab) 92
 potassium permanganate, pyloric stenosis (ab) 204
 procainamide overdose (ab) 145; fever, liver dysfunction (ab) 676
 propoxyphene, poisoning (ab) 676
 propranolol (ab) 42; (ab) 146; alopecia (ab) 93
 quinidine, fever, allergy (ab) 41
 rifampicin, hepatitis (ab) 494; acute renal failure (ab) 548
 salicylism, infant (ab) 495; 695
 succinylcholine, apnea (ab) 146
 sympathomimetic amine (ab) 496
 teratology, 690
 tetracycline, hepatotoxicity (ab) 448
 thioridazine, pigmentary retinopathy (ab) 42
 vancomycin, 520
 vasopressin-resistant diabetes insipidus from demeclocycline (ab) 41
 vincristine, coma (ab) 252; neurotoxicity (ab) 548
 vinyl chloride, liver angiosarcoma (ab) 547
Advertising, direct mail, influence on prescribing, 81
Age and Drug Effects, 632
 Alcohol, GI tract bleeding (ab) 447; interaction with isoniazid (ab) 145; relation to driving safety, 247; use among students (ab) 246
 Alcoholism, teratogenic effects, 692; therapy with peyote (ab) 717
 Aldomet, See Methylodopa
 Alexander, M. M. (author) abstracts, 722, 725
 Alexander, Michael R. (co-author) Methicillin Nephritis, 115; (author) abstracts, 722, 725; (author) letter correcting methicillin nephritis article, 445; A Review of Vancomycin Therapy After 15 Years of Use, 520
 Allwood, M. C. (co-author) letter concerning article on sterility of screw-capped bottle system, 74
 Ambulatory Pharmacy Service, patients' attitude toward, 710
 American Society of Hospital Pharmacists, editorial on Statement of Objectives, 511
 treated with physostigmine (letters) 114; 250
 Aminophylline, thiethylperazine incompatibility, 721
 Amitriptyline, overdose (letters) 78; overdose Amoxicillin, antimicrobial activity and pharmacology of (ab) 678; evaluation, 542; therapy in infections (ab) 206
 Amoxicillin, See Amoxicillin
 Amphetamine, bioavailability and pharmacokinetics (ab) 205
 Amp-Ce, See Ampicillin
 Ampicillin-resistant Haemophilus Influenzae Type B infection (ab) 616
 Analgesic Combinations, controlled evaluation of (ab) 615
 Ancef, See Cefazolin
 Ancones, See Flucytosine
 Anderson, Roger W. (co-author) Effectiveness of a Combined Drug Self-Administration and Patient Teaching Program, 374

Anectine, See Succinylcholine
 Angina Pectoris, ischemic heart disease, 382
 Anorexiants, interactions, 591
 Antacids, interaction with naproxen (ab) 675
 Antibiotic Therapy, of pyelonephritis, 512
 Anticholinesterase Agents, 255
 Anticoagulants, coumarin-type, drug interactions, 172; in cadaveric renal allografts (ab) 549
Anticoagulation Therapy, ophthalmodynamometry and subconjunctival hemorrhage (ab) 204
 Anticonvulsants, adverse drug reactions (ab) 496; teratology, 690
 Antidepressants, interactions with CNS psychotherapeutic agents, 591
 Antiepileptic Drugs, interaction with doxycycline (ab) 547
 Antihypertensive Drugs, interactions, 591
 Antipyrine, influence of thyroid status on half-life of (ab) 449
 L-Arginine Hydrochloride, investigational drug information, 663
 Argivene, 663
 Ascorbic Acid, interaction with aspirin (ab) 145
 Aspirin
 acute myocardial infarction (ab) 496
 adverse effects (ab) 42, 694
 drug interactions, 694
 hepatitis (ab) 205
 induced hepatotoxicity in S.L.E. (ab) 205
 interaction with ascorbic acid (ab) 145
 interaction with indomethacin (ab) 252
 teratogenic effects, 692
 Azathioprine, after 5 years (ab) 254
 Azolid, See Phenylbutazone

B

Bactocill, See Oxacillin
 Bartilucci, A. J. (author) Letter technologists, 720
 Bartle, William R. (author) letter concerning trimethoprim in prostatic fluid, 667
 Baycillin, See Propicillin
 Becker, Charles E. (author) letter concerning H.S. sedation, 493
 Bergman, H. D. (co-author) Clinical Pharmacy Activities in a VA Hospital, 656
 Bernstein, Diane (author) Drugs Known to React With Coumarin-Type Anticoagulants, 172
 Bioavailability, bioequivalence study panel report (ed) 461; digoxin malabsorption, 644; evaluating (letter) 401
 Biopharmaceutics, See also Pharmacokinetics
 amoxicillin, 542; cromolyn, 20; digoxin (ab) 94; vancomycin, 520
 Bloomfield, J. C. (author) Drug Information Sources, A Bibliography - 2nd Ed., 184
Books Received
 Accountability in Drug Education (A. L. Abrams, et al.) 263
 The Adolescent Gap - Research Findings on Drug Using and Non-Drug Using Teens (E. M. Scott, Ph.D.) 490
 Alcohol Detoxification Programs - Treatment Instead of Jail (H. H. Siegel) 490
 Alcoholism, Skid Row and the Police (A. Z. Cammagne, Ph.D., et al.) 264
 The American Heroin Empire (R. Kunnes, M.D.) 399
 The Amphetamines: Toxicity and Addiction, 2nd Ed. (O. J. Kalant) 399
 Before Addiction (F. Lieberman, P. Caroff & M. Gottesfeld) 490
 The Botany and Chemistry of Hallucinogens (R. E. Schultes, Ph.D. and A. Hofman, Ph.D.) 490

- Chemical and Biological Aspects of Drug Dependence (S. J. Mule, Ph.D. and H. Brill, M.D., ed.) 490
- Contemporary Problems of Drug Abuse (P. A. Levin, ed.) 399
- The De-Addiction Process (L. Brill) 264
- Dealing With Drug Abuse (P. M. Wald and P. B. Hutt) 490
- Dependence Liability of "Non-Narcotic" Drugs (H. Isbell & T. L. Chrusciel) 399
- DHEW Directory of Drug Education Programs and Materials, Vol. 2 (Macro Systems, Inc.) 490
- Drug Abuse and Drug Counseling, A Case Approach (T. Weisman) 490
- Drug Abuse - Current Concepts and Research (W. Keup, M.D., ed.) 399
- Drug Abuse in Industry (P. A. Carone, M.D. & L. W. Drinsky, Ph.D.) 264
- Drug Abuse in Industry (J. M. Scher, M.D., ed.) 490
- Drug Abuse Nonmedical Use of Dependence Producing Drugs (S. Btsh, ed.) 264
- Drug Dependence and Rehabilitation Approaches (R. E. Hardy & John G. Cull) 264
- The Etiology of Alcoholism (J. B. Roebuck, Ph.D. and R. G. Kessler) 490
- Everything You Wanted to Know About Drug Abuse . . . but were afraid to ask (C. L. Wineck) 666
- Hallucinogenic Drugs (C. R. Brown, Ph.D.) 264
- Interaction of Alcohol and Other Drugs, 2nd Ed. (E. Polacek) 490
- Legal Dimensions of Drug Abuse in the United States (H. R. Levine) 399
- Licit & Illicit Drugs (E. M. Brecher, ed.) 264
- Major Modalities in the Treatment of Drug Abuse (L. Brill & L. Lieberman) 264
- Methadone: Experiences and Issues (C. E. Chambers & L. Brill) 264
- The Narcotic Officers Notebook, 2nd Ed. (M. L. Harney and J. G. Cross) 399
- Narcotics and Narcotic Addiction (D. W. Maurer, Ph.D. and V. H. Vogel) 490
- The Para-Professional in the Treatment of Alcoholism - A New Profession (G. E. Staub and L. M. Kent) 490
- Progress in Drug Abuse (P. H. Blachly, M.D., ed.) 263
- Recovery from Alcoholism: A Social Treatment (R. G. O'Brian, M.D. and H. Lennard, Ph.D.) 490
- Rehabilitation of the Drug Abuser with Delinquent Behavior (R. E. Hardy & J. G. Cull) 399
- Rehabilitation of Urban Disadvantaged (R. E. Hardy & J. G. Cull) 399
- Ups and Downs Drugging and Duping (J. Rice, M.D.) 490
- The Use of Cannabis (Report of WHO Scientific Group, WHO) 666
- Uses of Marijuana (S. N. Snyder, M.D.) 490
- Books Reviewed**
- The American Medical Machine (A. Ribicoff and P. Danaceau) 666
- Computer Oriented Comprehensive Pharmacy Service (Journal of Clinical Computing) 399
- Diabetes Mellitus, Diagnosis and Treatment (S. S. Fajans, M.D. and K. E. Sussman, ed.) 263
- Handbook of Drug Interactions, 2nd Ed. (E. A. Hartshorn) 195
- Hazardous to Your Health: A New Look at the "Health Care Crisis" in America (M. H. Edwards) 488
- Hospital Pharmacy, 3rd Ed. (Wm. E. Hassan, Jr.) 665
- In Critical Condition: The Crisis in America's Health Care (E. M. Kennedy) 489
- Pediatric Therapy (H. C. Shirkey, ed.) 490
- Poverty, Ethnic Identity and Health Care (B. Bullough and V. Bullough) 489
- Progress in Medicinal Chemistry (G. P. Ellis and G. B. West, ed.) 665
- Public Expectations and Health Care: Essays on the Changing Organization of Health Services (D. Mechanic, Ph.D.) 398
- Side Effects of Drugs, Volume 7 (L. Meyler & A. Herxheimer, ed.) 398
- Survey of Present and Future Pharmaceutical Studies in the Member States of the Council For Cultural Cooperation of the Council of Europe (K. Steiger-Trippi) 195
- The United States Dispensary (A. Osol and R. Pratt, ed.) 665
- USAN 10 and the USP Dictionary of Drug Names, and 1973 Supplement (M. C. Griffiths, ed.) 263
- Bosso, John A. (co-author) Cystic Fibrosis, The Pharmacist's Role, 58
- Bottles, Sterility of Screw Capped System, 74
- Bradykinin, investigational drug, 25
- Brain Syndrome in elderly, 476
- Branson, Joanne B. (author) book reviews, 195, 263, 665
- Brettschneider, C. K. (author) book review, 263
- Brispen, See Diclaxacillin
- Brocillin, See Propicillin
- Bronchial Asthma, use of cromolyn, 20
- Brownell, Kenneth W. (co-author) letter concerning medicines for cardiorespiratory arrest, 32
- Butazolidin, See Phenylbutazone
- C**
- Calcium Fusarate Complex, investigational drug, 26
- Callidin I, investigational drug, 25
- Campbell, W. B. (author) Letter relative to Compazine-Thorazine errors in Journal, 721
- Camphorated Oil, adverse effects, 692
- Carbamazepine, drug action (ab) 206
- Carbenicillin, hemostatic defect from (ab) 677; interactions with gentamicin (ab) 93
- Cardiorespiratory Arrest, drugs for, 32
- Catalano, Robert B. (co-author) Effect of Packaging and Instruction on Outpatient Compliance with Medication Regimens, 10
- Catecholamine, interaction with cocaine (ab) 39
- Cefadyl, See Cefapirin, Cephapirin
- Cefazolin, compared with other cephalosporins (ab) 93; serum levels and urinary recovery (ab) 253
- Cefoxitin, comparison with cephalothin (ab) 253
- Celbenin, See Methicillin
- Cellulose Phosphate, investigational drug information, 183
- Cephadyl, See Cephapirin
- Cephalexin, nephrotoxicity (ab) 548
- Cephaloridine, serum levels and urinary recovery (ab) 253
- Cephalothin, comparison with cefoxitin (ab) 253; IV administration, adverse reactions (ab) 409; serum levels and urinary recovery (ab) 253; toxic paranoic reaction, 71
- Cephapirin, IV adverse reactions (ab) 409
- Cetacillin, See Propicillin
- Chain Drug Stores, reversal of Liggett decision 7, 27; repelling practices, 221; letters re editorial 248; 492
- Cheese and Drug Interactions, 591
- Chinese Herb Medications, agranulocytosis (ab) 676
- Cholestyramine, digitalis toxicity, 706
- Choloxin, See Thyroxine
- Chubb, James M. (co-author) The Pharmacist's Role in Preventing Medication Errors, 430
- Chudzik, Gregory M. (co-author) Cystic Fibrosis, The Pharmacist's Role, 58
- Cincinnati, Decentralized Pharmacy, 231
- Cigarette Smoking, retards fetal growth, 692
- Clinical Drug Trials, design of, 528, 531
- Clinical Pharmacology, alliance with clinical pharmacy (ab) 245; (ab) 201
- Clinical Pharmacy**
- activities in VA Hospital, 656
- alliance with clinical pharmacology (ab) 245
- attitudes of pharmacists toward, 238
- dilemma, 483; letter commenting on, 612
- directions for (ed) 631
- education information on (letters) 74
- legal barriers, 483
- need for community roles, 65
- pharmacist's role, 656
- pharmacist's role in cystic fibrosis, 58
- pharmacist's role in emergency case, 392
- pharmacist's role in group practice with physician, 572
- pharmacist's role in instructing patient, 10, 20, 58, 374, 422, 430, 572
- pharmacist's role in monitoring parenteral nutrition, 576
- pharmacist's role in primary health care, 572 and pharmacology (ab) 201
- in primary health care, 572
- role in reducing drug costs, 108
- schools of pharmacy, roles, 69
- service for society, 65
- Clinical Pharmacy and Pharmacology, Friends or Foes (ab) 201**
- Clinical Pharmacy Case Studies**
- Acute Brain Syndrome in an Elderly Patient, 476; Acute Nitrofurantoin Pneumonia, 16; Bacterial Infection of the Skin and Considerations in Drug Therapy, 535; Cystic Fibrosis, 58; Digitalis Toxicity, 700; Diphenylhydantoin Dosing, 462; Extraparacardiac Parkinson-Like Reactions to Phenothiazines, 166; Generalized Seizure Disorder, 581; Gentamicin Therapy, 650; Ischemic Heart Disease - Angina Pectoris, 382; Methicillin Nephritis, 115; Myasthenia Gravis, 255
- Clinical Pharmacy Services, attitudes of physicians and nurses toward, 231**
- Clinical Trials, design, 528, 531**
- Clonidine, menopausal flushing (ab) 496
- Closson, Richard (author) Foreign Drug Identification, 437
- CNS Depressants, interactions, 591
- CNS Stimulants, interactions, 591
- Cocaine, interaction with catecholamine (ab) 39
- Cohen, Michael R. (co-author) letter concerning medicines for cardiorespiratory arrest, 32
- Colestil, See Colestipol
- Colestipol, digitoxin toxicity, 706
- Community Pharmacy, approaching the future, 65; relations between price and quality, in (ab) 247; reversal of Liggett decision (ed) 7, 27; letters 248, 492; in Soviet Union (ed) 688
- Compazine, See Prochlorperazine
- Compliance, patient, effect of packaging and instruction on, 10
- Compounder, evaluation of pharmacist as, 242
- Conaty, Robert B. (author) letter concerning study of hospital pharmacy technicians, 143
- Consultant, evaluation of pharmacist as, 242
- Contamination, pathogens in water with ornamental fish (ab) 720
- Continuing Education, DICP's role, 78; mandatory or optional (ed) 373; comment on editorial, 612
- Cooperative Drug Trials, methodology, 531
- Corticosteroids, filtering blebs after cataract extraction (ab) 495; induced uveitis (ab) 448
- Cost Comparisons, medications systems, 178
- Cost Feasibility, of pharmacist in primary health care, 572
- Coumadin, See Warfarin
- Coumarin-Type Anticoagulants, drug interactions, 172
- Cromolyn Sodium, evaluation, 20; treatment of asthma (ab) 94; biopharmaceutics, 20
- Cuemid, See Cholestyramine
- Cupit, Gary C. (co-author) Pharmacist's Role in Monitoring Total Parenteral Nutrition, 576
- Curatin, See Doxepin
- Cyclopam, See Tetracycline
- Cyclophosphamide (ab) 497; bladder toxicity (ab) 41
- Cystic Fibrosis, the pharmacist's role, 58
- Cytosan, See Cyclophosphamide
- D**
- Darvon, See Propoxyphene
- Davis, John M. (co-author) Drug Interactions Involving the Drugs of Abuse, 120
- Debrisoquine, interaction with phenylephrine (ab) 408
- Declinox, See Debrisoquine
- Declomycin, See Demeclocycline
- Demeclocycline, nephrogenic diabetes insipidus (ab) 150; vasopressin-resistant diabetes insipidus (ab) 41
- Der, Nelson (co-author) letter concerning Dilantin piggybacks, 491
- Detail Men, influence in prescribing, 81
- Devine, Ben J. (author) Gentamicin Therapy, 650
- Diabetes Mellitus, glucose urine testing systems, 422
- Diagnostic Tests, cystic fibrosis, 58; myasthenia gravis, 255; seizure disorders, 581
- Diamox, See Acetazolamide
- Diapers, soiled, as a source of viruses (ab) 718
- DIAS Rounds, 437
- Diazepam, in seizure disorders, 581; and N-desmethyldiazepam, plasma concentrations (ab) 615
- Diazoxide, letter concerning evaluation, 34
- Dibromodulcitol, investigational drug, 26
- Dicloxacillin, combination with propicillin for pseudomonas aeruginosa infections (ab) 39
- Diffusion of Drugs, partition coefficient, 470; into prostatic fluid and milk, 470
- Digitalis, recent advances (ab) 497; toxicity, 700
- Digitoxin, dosage, 700; toxicity, 700
- Digoxin, dosing regimens, 222; evaluation of bioavailability (ab) 94; malabsorption, 644; pharmacokinetics of interpreting bioavailability (ab) 150; plasma levels, dose and renal function (ab) 410; serum concentration, frequency of digitoxicity (ab) 677; serum concentrations (ab) 411; toxicity, reduction of (ab) 495; 700
- Dilantin, See Diphenylhydantoin
- Dimethyl Sulfoxide, toxicity (Letter) 558
- Diphenylhydantoin, congenital malformations (ab) 204; digitoxin toxicity, 706; dosing, factors influencing, 462; hepatic necrosis (ab) 676; interaction with methylphenidate, (Letters) 720; piggybacks, use of alcohol in (letters) 491; plasma disappearance (ab) 206; pure RBC aplasia (ab) 548; in seizure disorders, 581; teratology, 690
- Dipyridamole, in cadaveric renal allografts (ab) 549
- Ditter, Louis W. (author) Pharmacokinetic Considerations in Clinical Drug Trials, 222
- Doxepin, with alcohol, relationship to driving safety (ab) 247
- Doxycel, See Doxycycline
- Doxycycline, excretion with altered urinary pH (ab) 205; interaction with antiepileptic drugs (ab) 547; kinetics (ab) 678
- Drimany, Randall Kent (author) letter on lidocaine dosage, 613
- Driving Safety and Drugs (ab) 247
- Drug Absorption, digoxin malabsorption, 644

Drug Abuse, adolescents (ab) 406; among secondary school students (ab) 246; chloro-dyne dependence (ab) 720; interaction of, 120

Drug Actions, Interactions and Reactions, 39, 92, 145, 203, 251, 408, 447, 494, 547, 615, 675, 722

Drug Administration, deviation in, 656; problems in the elderly, 632; patient self-administration, 374

Drug Bioequivalence Study Panel, report from (ed) 461

Drug Compounding, lack of accuracy, 242

Drug Costs, drug utilization review, 108; controlling antibiotic costs (Letter) 402; drug expense comparison (Letter) 402; effect of drug distribution system on, 178; H. S. Sedation (Letter) 250; in N. Y. Medicaid program (ab) 718; relation to quality (ab) 247

Drug Diffusion, into prostatic fluid and milk, 470

Drug Distribution Systems, cost comparisons, 178

Drug Dosage
antibiotics, in pharyngeal gonorrhea (letter) 491
diphenylhydantoin, 462
gentamicin dosage, nomogram (ab) 448
influence of elimination rate, 228
kanamycin regimens, 229
pharmacokinetic considerations, 222

Drug Evaluation, methodology, 528, 531

Drug Evaluation Data, Amoxicillin, 542; Cromolyn Sodium, 20

Drug History Interview, 374

Drug Identification, of foreign drugs, 437; australian sources (letter) 728; additional sources (letter) 669

Drug-Induced Blood Dyscrasias (ab) 203

Drug Information Analysis Service, 437

Drug Information, investigational, cellulose phosphate, 183; etiocholanolone, 183; foreign drug identification, 437; tyramine, 182

Drug Information Sources, A Bibliography—2nd Ed., 184; influence on prescribing habits, 81

Drug Innovations, theoretical models, 89

Drug Interactions
alcohol-isoniazid, effects on psychomotor skills (ab) 145
amoxicillin, 542
amphetamines, 125
antacids, naproxen absorption (ab) 675
antidepressants, psychotherapeutic agents, 591
antiepileptic drugs, doxycycline (ab) 547
ascorbic acid-aspirin (ab) 145
aspirin, 694
barbiturates, 135
bibliography of publications, 487
carbenicillin, gentamicin, against enterococci (ab) 93
cathcholamine-cocaine (ab) 39
cocaine-cathcholamine (ab) 39
coumarin-type anticoagulants, 172
debrisoquine-phenylephrine (ab) 408
dicloxacillin-propicillin, in *Pseudomonas* infections (ab) 39
diphenylhydantoin dosing, renal failure, 462
doxycycline, antiepileptic drugs (ab) 547
drug metabolism, oral contraceptives (ab) 251
drugs of abuse, 120
epinephrine, propranolol (ab) 251
evaluation of (Letters) 720
gentamicin-carbenicillin, against enterococci (ab) 93
geriatric patient, 632
heparin-neomycin (ab) 39
hypertension, methyldopa-induced (ab) 203
indomethacin-aspirin, effect on serum concentrations (ab) 252
isoniazid-alcohol, effects on psychomotor skills (ab) 145
laboratory tests, oral contraceptives (ab) 617
levodopa-L-methionine (ab) 617
mercaptopurine-warfarin (ab) 616
L-methionine-levodopa (ab) 617
methyldopa-induced hypertension (ab) 203
methylphenidate-diphenylhydantoin, (Letters) 720
methysergide maleate, tolbutamide-mediated insulin release (ab) 251
monoamine oxidase inhibitors, 125
naproxen-antacids (ab) 675
narcotics, 129
neomycin, heparin (ab) 39
oral contraceptives, drug metabolism (ab) 251; laboratory tests (ab) 617
phenylbutazone-tolbutamide (ab) 203, 494
propicillin-dicloxacillin in *Pseudomonas* infections (ab) 39
propranolol-epinephrine (ab) 251
psychotherapeutic agents, antidepressants, 591
streptomycin, vancomycin against enterococci (ab) 41
thiethylperazine-aminophylline (letter) 558
tolbutamide, insulin release, methysergide maleate (ab) 251; phenylbutazone (ab) 203, 494

vancomycin, gentamicin, against enterococci (ab) 41
warfarin-mercaptopurine (ab) 616

Drug Prescribing, habits of physicians, 81; patterns in N. Y. Medicaid (ab) 718

Drug Product Selection, repeal of ant substitution laws (letters) 142, 402; bioavailability letters, 401, 559

Drug Samples, influence on prescribing, 181

Drug Self-Administration, 373

Drug Services, See Pharmacy Services

Drug Substitution, repeal of laws (letters) 142

Drug System Services in HMOs (ab) 406

Drug Therapy, angina pectoris, 382; bacterial infection of skin, 541; cardiac and hyperlipoproteinemic outpatients, medication errors, 430; cromolyn bronchial asthma, 20; cystic fibrosis, 58; epilepsy, 581; myasthenia gravis, 255; nitrates in angina pectoris, 382; prescribing habits, 81; propranolol in angina pectoris, 382; seizure disorders, 581; self-administration, 374; skin infections, case study, 535

Drug Utilization, acknowledgement, 491; antibiotic usage, 108; clinical pharmacist's role, 108

Drugs, for cardiorespiratory arrest, 32; as cause of brain syndrome, 476; and driving, 247; and the geriatric patient, 632; new, and prescribing habits, 81

Dulcitol, Dibromo, investigational drug, 26

Dynapen, See Diclloxacin

E

Ebel, John A. (author) letter on continuing education, 612

Economics of Community Practice, 65

Editorials by D. E. Francke, On Accepting Things as They Are, 221; Adverse Drug Reactions in Perspective, 571; Continuing Education - Mandatory or Optional? 373; Directions for Clinical Pharmacy, 631; The Importance of an Historical Perspective, 55; Impressions of Community Pharmacy in the Soviet Union, 688; Specialization in Pharmacy, 105; Student Evaluation of Teachers, 163; The Supreme Court's Reversal of the Liggett Decision, 7

Editorial by W. M. Heller, guest editor, Report from the Drug Bioequivalence Study Panel to the Office of Technology Assessment, 461

Editorials by H. A. K. Whitney, Jr., New Goals for the ASHP: Opportunity Knocks Only Once? 511; The Pharmacy Technologist: A New Assistant for The Clinical Pharmacist, 421

Education, and community pharmacy, 63; continuing (ed) 373; emergency care situations, 392; student evaluation of teachers (ed) 163

Efedex, See Fluorouracil

EKKO Sr. and Jr., See Diphenylhydantoin

Elantrine, in Parkinsonism (ab) 206

Elavil, See Amitriptyline

Emergency Care, pharmacist's contribution, 392

Ensey, Russel (co-author) Methicillin Nephritis, 115

Ephedrine, evaluation of bronchodilator efficacy (ab) 448

Epilepsies, drug therapy, 581

Errors, Compazine-Thorazine, 169

Eshelman, Fred (author) abstracts, 42, 448, 495, 676, 678

Estrogen, adverse reactions (ab) 409

Ethylendiamine Tetracetate Acid, digoxin toxicity, 705

Etiocholanolone, investigational drug information, 183

Evaluation, controlled, analgesic combinations, drug actions, 615

Evaluation of Teachers, letter commenting on editorial, 491

Euthroid, See Thyroxine

Excedrin P.M., and placebo (ab) 412

Extended Care Facilities, clinical pharmacists in, 108

F

Fenoprofen, in osteoarthritis (ab) 549

FIP members in the United States, 44, 198, 590

Flack, Herbert L. (co-author) Effect of Packaging and Instruction on Outpatient Compliance with Medication Regimens, 10

Fletcher, H. P. (co-author) Clinical Pharmacy Activities in a VA Hospital, 656

Flucytosine, fatal aplastic anemia from (ab) 676

Fluorinated Steroids, adverse reaction (ab) 548

5-Fluorocytosine, impaired renal function (ab) 205

5-Fluorouracil (ab) 409

Food, and Monoamine Oxidase Inhibitors, interactions, 591; effect on absorption and excretion of amoxicillin, 545

Foreign Drug Identification, 437

Francke, Donald E. (editorials) On Accepting Things as They Are, 221; Adverse Drug Reactions in Perspective, 571; Continuing

Education - Mandatory or Optional? 373; Directions for Clinical Pharmacy, 631; The Importance of an Historical Perspective, 55; Impressions of Community Pharmacy in the Soviet Union, 688; Specialization in Pharmacy, 105; Student Evaluation of Teachers, 163; The Supreme Court's Reversal of the Liggett Decision, 7

Freeman, Stanley H. (author) letter concerning controlling drug costs, 402

Fry, L. K. (co-author) letter concerning insulin and dead space volume, 33

Furadil, See Nitrofurantoin

Furosemide, pharmacokinetics (ab) 410

G

Galactitol Derivative, investigational drug, 26

Gallelli, Joseph F. (co-author) Investigational Drug Information, 25, 182, 663

Garamycin, See Gentamicin

Garretson, Lorne K. (author) letter Relative to Evaluation of Methylphenidate-Diphenylhydantoin Interaction, 720

Gavin, Patrick W. (co-author) The Pharmacist as Compounder and Consultant, 242

Gee, Lana (co-author) letter concerning H.S. sedation, 493; letter concerning trimethoprim diffusion into prostatic fluid, 667

Generic Prescribing, effect on drug costs (ab) 718

Gentamicin, in biliary tract (ab) 93; interaction with carbenicillin (ab) 93; pharmacokinetics (ab) 43; prescribing aids for (ab) 448; serum levels (ab) 497; synergism with vancomycin against enterococci (ab) 41

Gentamicin Therapy, 650

Geopen, See Carbenicillin Disodium

Geriatrics, brain syndrome, 476; drug problems, 632; role of drugs, 108

Glucose Urine Testing Systems, 422; correction on, 493

Glycerol, adverse reactions (ab) 408

Goicoechea, Frank J. (author) Ischemic Heart Disease-Angina Pectoris, Case Study, 382

Gonorrhea, pharyngeal, letter regarding dosage of antibiotics, 491

Gordon, R. B. (co-author) letter concerning drug interaction with thiethylperazine, 558

Griffin, Gerald D. (author) The Dilemma of Clinical Pharmacy, 483

H

Hagans, James (author) The Design and Methodology of Cooperative Drug Trials, 531

Hahn, Tom (co-author) Attitudes of Physicians and Nurses Exposed to Pharmacists Providing Twenty-four Hour Service in the Satellite Pharmacy of a Medical Center, 231

Hambleton, R. (co-author) letter concerning article on sterility of screw-capped bottle system, 74

Hartshorn, Edward A. (author) Interactions of CNS Psychotherapeutic Agents - Antidepressants, 591

Hays, Dennis P. (author) letter concerning evaluating bioavailability, 401

Health Care Sociology, 27, 201, 245, 405, 718

Health Maintenance Organizations, drug system services (ab) 406

Heller, William M. (editorial) Report from the Drug Bioequivalence Study Panel to the Office of Technology Assessment, 461

Helling, Dennis K. (author) book review, 488

Hemocyanin, keyhole limpet, (investigational drug) 683

Hendeles, Leslie (author) letter concerning pharyngeal gonococcal infection, 491; (co-author) letter on thioctic acid availability, 614

Heparin, disseminated intravascular coagulation (ab) 495; interaction with neomycin (ab) 39; low-dose SQ, versus oral anticoagulants (ab) 449; ophthalmodynamometry and subconjunctival hemorrhage (ab) 204; for pulmonary embolism (ab) 496

Hepler, Charles D. (co-author) letter on thioctic acid availability, 614

Herman, Colman M. (co-author) The Development and Testing of a Methodology to Measure the Attitudes of Pharmacists Toward Clinical Pharmacy, 238

Heroin Addiction, fetal complications of (ab) 150

Hexachlorophene, poisoning & death (ab) 447

Hiatt, Robert A. (author) Generalized Seizure Disorder, 581

Hirakawa, Paul K. (co-author) Investigational Drug Information, 683

Hirschman, J. L. (co-author) The DIAS Rounds, 437

History of Pharmacy (ed) 55

HMO's drug services (ab) 406

Hoffmann, Richard P. (author) response to letter concerning electrolyte contents of Polynute Pack, 35

Holloway, Donald A. (author) Drug Problems in the Geriatric Patient, 632

Hospitals, physician's power and influence (ab) 718

House Organs, influence on prescribing, 81
Hurst, Marlene (author) letter concerning micro-filming of DICP, 35
Hyperactive Children, placebo-controlled follow-up (ab) 616
Hyperalimentation, pharmacist's role in monitoring, 576
Hyperalimentation Solution, mineral content (letter) 34
Hyperstat, See Diazoxide
Hypnotics, H.S. Sedation (letters) 250, 493
Hypokalemia, in acute brain syndrome, 476

I

Imhoff, Thomas (author) abstracts, 39, 42, 92, 409, 618, 617
Imipramine, teratogenic effects, 691
Impetigo, therapy, 541
Imuran, See Azathioprine
Incompatibility Study, Intralipid, 75
Inderal, See Propranolol
Indocin, See Indomethacin
Infant Salicylism (ab) 495
INH, See Isoniazid
Instruction of Patient, relationship with compliance, 10
Insulin and Dead Space Volume, 33
Insulin, induced hypoglycemia (ab) 447; insulin and non-insulin diabetics, 422
Intal, See Cromolyn, 20
International Pharmaceutical Federation, application blank and members, 44, 198, 590
Intralipid Infusions, adverse drug reactions (ab) 145, compatibility study, 75
Intravenous Pyelography, acute renal failure (ab) 548
Investigational Drug Information, L-Arginine, 663; Bradykinin, 25; Calcium Fusarate Complex, 26; Cellulose Phosphate, 183; Dibromodulcitol, 26; Etiocholanolone, 183; Keyhole Limpet Hemocyanin, 663; NSC-104800, 26; Thyrotropin Releasing Hormone, 664; Tyramine, 182
Investigational Drugs, pharmacokinetic considerations, 222
Ionamin, See Phenentermine Resin
Ischemic heart disease, angina pectoris, 382
Isoniazid, interaction with alcohol (ab) 145
Isophrin, See Phenylephrine

J

Jackson, Eric (author) abstracts, 678
Janowsky, Davis S. (co-author) Drug Interactions Involving the Drugs of Abuse, 120
Jansen, James R. (author) Letter, incompatibility of thiethylperazine-aminophylline, 721
Jeffery, William H. (author) letter concerning drug abuse interactions, 403
Jones, G. J. (author) letter concerning use of DICP in continuing education, 78
Jones, Mark E. (author) abstracts, 92, 93, 204, 447, 448, 495, 496, 676, 677
Journals, influence on prescribing, 81
Juhl, Randy P. (co-author) Family Practitioner-Clinical Pharmacist Group Practice, 572

K

Kallidin, I, investigational drug, 25
Kanamycin, dosing regimens, 222; pharmacokinetics following IM administration (ab) 42
Kantrex, See Kanamycin
Kayne, Ronald C. (author) Acute Brain Syndrome in an Elderly Patient, 476
Keflex, See Cephalaxin
Keflin, See Cephalothin
Kefzol, See Cefazolin
Keller, Susan M. (co-author) The Pharmacist as Compounder and Consultant, 242
Kellick, Kenneth A. (author) letter concerning lidocaine drip, 492
Keyhole Limpet Hemocyanin, investigational drug information, 663
Kinetics, distribution, related to pyelonephritis, 512
Kleinman, Larry M. (co-author) Investigational Drug Information, 25, 182, 663
KLH, Keyhole Limpet Hemocyanin, 663
Knowles, Jimmy H. (author) abstracts, 722
Kochevar, Marty (co-author) letter concerning insulin and dead space volume, 33
Koda, Robert T. (co-author) Diffusion of Drugs into Prostatic Fluid and Milk, 470; Letter, 668
Kohan, Samuel (co-author) letter concerning article on use of antiparkinson drugs, 444
Koup, Jeffrey R. (co-author) Suspected Digoxin Malabsorption, 644
Kradjan, Wayne A. (author) Factors Influencing Diphenylhydantoin Dosing, 462
Krenzelo, Edward P. (author) letter concerning technologists and clinical pharmacists, 559
Kuwahara, Jean (co-author) Diffusion of Drugs into Prostatic Fluid and Milk, 470; Letter, 668

L

Labeling, use of auxiliary labels, 242
Labeling Medication, role of pharmacist, 242
Laboratory Tests, amoxicillin effects of, 545; effects of oral contraceptives on (ab) 617; error in Perspectives in Clinical Pharmacy, 71
Lande, Nancy Waterman (author) Extraparadigmatic Parkinson-Like Reactions to Phenothiazines, 166; (author) response to letter on antiparkinson drug article, 444
Lanoxin, See Digoxin
Laradopa, See Levodopa
Larocin, See amoxicillin
Lasix, See Furosemide
Lauper, R. David (author) Drug Evaluation Data, 542
Law and Clinical Pharmacy, 483
Leary, Scott (author) letter concerning student evaluation of teachers, 491
Lee, Robert E. (author) book review, 666
Letourneau, Ken N. (author) Drug Utilization Review in an Extended Care Facility, 108; (author) letter concerning drug utilization acknowledgments, 491
Letter, See Thyroxine
Letters to the Editor
on accepting things as they are, 492
amitriptyline overdose, 78; 250; physostigmine in, 144
antiparkinson drugs, use of, reader comment and author response, 444
antistubstitution laws, repeal, 142
bioavailability, evaluating, 401; 559
brand interchange, 402
cephalothin, toxic paranoic reaction, 71
clinical pharmacy, dilemma of, 612
community pharmacy, future of, 248
compazine and thiorazine, 721
controlling drug costs, 402
diazoxide evaluation, 34
DICP & continuing education, 78
DICP, microfilming of, 35
Dilantin piggybacks, 491
DMSO toxicity, self-induced, 558
drug abuse interactions, 403
drug expense comparison, further data, 403
drug utilization acknowledgments, 491
education, clinical pharmacy, 74; continuing, 612
electrolyte contents of Polynute Pack, author response, 35
evaluation of drug interactions, 720
FIP Bulletin Cover, objection to, 250
glucose urine testing systems, 493
gonorrhea, pharyngeal, antibiotics in, 491
hospital pharmacy technicians, study of, 143
H.S. sedation, 250; 493
hyperalimentation solution, mineral content, 34
identifying foreign drugs, 669
insulin and dead space volume, 33
intralipid compatibility study, 75
IV container, additive technique for, 248
IV incompatibility, thiethylperazine-aminophylline, 721
lidocaine dosage, 613; Dennis Lichon's reply, 613; lidocaine drip, 613; IV additive technique, 248
Liggett Decision, letter commenting on editorial, 248
medicines for cardiorespiratory arrest, comments and author response, 32
methicillin nephritis, correction, 445
minocycline use in renal impairment, 71
myasthenia gravis, correction in figure, 445
new goals for the ASHP, 721
pharmacokinetic considerations in clinical drug trials, 556
pharmacy technologists, 614, 720
pharyngeal gonococcal infection, 491
physostigmine in amitriptyline overdose, 144
selected laboratory tests, error, 71
specialization in pharmacy, 400, 445
specialization in pharmacy, comment and editor response, 400, 444
sterility of screw-capped bottle system, 74
student evaluation of teachers, 491
study of hospital pharmacy technicians, 143
technologists and clinical pharmacists, 559, 669
thiethylperazine, drug interaction with, 558
thiotic acid availability, 614
trimethoprim diffusion into prostatic fluid, 667
trimethoprim-sulfamethoxazole in prostatitis, 668
Levodopa, adverse reactions (ab) 92; interaction with L-methionine (ab) 617; variation of metabolism with G.I. absorption site (ab) 449
Levodopa, See Thyroxine
Lichon, Dennis S. (author) reply to letter from Kenneth A. Kellick, 613 (Letter) 248
Lidocaine, digitoxin toxicity, 706
Lidocaine Drip, 492; IV Additive technique (Letter) 248; comment on technique (Letter) 492; lidocaine dosage (Letter) 613; Dennis

Lichon's reply, 613
Lien, Eric J. (co-author) Diffusion of Drugs into Prostatic Fluid and Milk, 470; Letter, 668
Liggett Decision, (ed) 7; text of reversal by Supreme Court, 27
Lincomin, See Lincomycin
Lincomycin, colitis (ab) 146; intrathecal administration (ab) 42
Linkewich, Joseph A. (co-author) Effect of Packaging and Instruction on Outpatient Compliance with Medication Regimens, 10
Lipman, Arthur G. (author) letter on dilemma of clinical pharmacy, 612
Literature, 195, 263, 398, 488, 665
Lithium Carbonate, neonatal toxicity, 690
Lithotabs, See Lithium Carbonate
Lomonte, Peter J. (author) letter concerning technologists and clinical pharmacists, 669
Lomonte, V. A., Jr. (author) letter concerning specialization in pharmacy, 400
Loridine, See Cephaloridine
LSD, carotid artery occlusion following ingestion of (ab) 495
Lynn, Brian (author) letter concerning intralipid compatibility study, 75
Lysinger, Ronald C. (author) letter concerning specialization in pharmacy, 400

Mc

McCarron, Margaret M. (editor) Clinical Pharmacy Case Studies, 16, 166, 225, 382, 476, 535, 581, 650, 700
McCoys, Linda K. (author) abstracts, 495
McLeod, Don C. (editor) Drug Evaluation Data, 20, 542; (author) letter concerning diazoxide evaluation, 34; (author) letter concerning minocycline use in renal impairment, 71; (author) letter on pharmacy technologists, 614

M

Macroclantin, See Nitrofurantoin
Mail-Order Prescription Industry (ab) 405
Martin, L. Robert (co-author) Family Practitioner - Clinical Pharmacist Group Practice, 572
Maybino, Mary (co-author) letter concerning Dilantin piggybacks, 491
Mebaral, See Mephobarbital
Medication Errors, 430
Mellaril, See Thioridazine
Mental Disturbance, acute brain syndrome, 476
Mephentytol, in seizure disorders, 581
Mephobarbital, in seizure disorders, 581
Mercaptopurine, interaction with warfarin (ab) 616
Mesantoine, See Mephentytol
Mescaline, See Peyote, 717
Metallic mercury, enterocutaneous fistula from (ab) 495
Methicillin, nephritis, antibodies in (ab) 677
Methicillin Nephritis, case report, 115; correction in Table 1, 445
L-Methionine, interaction with levodopa (ab) 617
Methohexitone, comparison of induction doses of (ab) 549
Methotrexate, paraplegia (ab) 204; psoriasis, liver injury (ab) 146
Methoxyflurane, adverse drug reactions (ab) 494
Methyldopa, failure in Bartter's Syndrome (ab) 678; induced hypertension (ab) 203
Methylene Blue, necrotic subcutaneous abscesses from (ab) 677
Methylmethionin-Sulfonium Chloride, (Vit. U), antitumor action of (ab) 678
Methylphenidate, comment on reported interaction (Letter) 403; interaction with diphenylhydantoin (Letter) 720
15(R) Methylprostaglandin E₂ Methyl Ester, and Gastric Ulcers (ab) 615
Microfilming of DICP (letter) 35
Milk, diffusion of drugs into, 470
Miller, Paul G., Jr. (author) letter concerning May article on pharmacokinetic considerations in clinical drug trials, 556
Miller, Russell R. (author) letter on identifying foreign drugs, 669; Prescribing Habits of Physicians, Part VII: 81, Part VIII: 89
Minocin, See Minocycline
Minocycline, use in renal impairment (letters) 71
Mitani, Gladys Moriguchi (author) Acute Nitrofurantoin Pneumonia, case study, 16
Monitoring, total parenteral nutrition, 576
Monoamine Oxidase Inhibitors, interactions, 591
Morrill, Rita B. (co-author) letter concerning article on use of antiparkinson drugs, 444
Murray, Gordon (author) letter on cephalothin, toxic paranoic reaction, 71
Mushroom Poisoning, thiotic acid for (letter) 614
Myambutol, See Ethambutol
Myasthenia Gravis, case study, 255
Mycifradin, See Neomycin

N

Nalidixic Acid, intracranial hypertension and papilledema (ab) 204

Naloxone, for treatment of methadone poisoning (ab) 132

Naproxen, interaction with antacids (ab) 675

Narcosis, See **Naloxone**

Narcotic Drug Interactions, 120

NeyGram, See **Nalidixic Acid**

Nelson, Clyde J. (author) **Glucose Urine Testing Systems for the Pharmacist Teaching the Diabetic Patient**, 422

Neomycin, interaction with heparin (ab) 39

Neo-Synephrine, See **Phenylephrine**

Neurologic Examination, seizure disorders, 581

Newcomer, Darrell R. (co-author) **Effectiveness of a Combined Drug Self-Administration and Patient Teaching Program**, 374

Nicotinic Acid, adverse reactions (ab) 92

Nitrates, evaluation of long-acting (ab) 411

Nitrites, in angina pectoris, 382

Nitroblue Tetrazolium Test, in pyogenic arthritis (ab) 549

Nitrofurantoin, pneumonia, 16

Nomograms
for evaluating endogenous creatinine clearance, 650
for gentamicin dosage in renal failure, 650
gentamicin dosage, nomogram, 448

Norethisterone Acetate, in advanced breast cancer (ab) 254

Norwood, G. Joseph (co-author) **Family Practitioner - Clinical Pharmacist Group Practice**, 572

NSC - 50908E, 183

Nurses, attitude toward twenty-four hour clinical pharmacy service, 231

Nydrasid, See **Isoniazid**

O

Oderda, Gary M. (author) letter concerning amitriptyline overdose, 78

Oksa, Richard M. (author) letter concerning self-induced DMSO toxicity, 558

Omnipectin, See **Ampicillin**

Oncovin, See **Vincristine**

Oral Contraceptives, coagulation changes induced by (ab) 675; cryptogenic cerebral embolism (ab) 205; effects on laboratory tests (ab) 617

Oricillin, See **Propicillin**

Orinase, See **Tolbutamide**

Outpatient Pharmacy Service, attitude of patients toward, 710

Outpatients, compliance with medication, 10; medication errors, 430; regimens, 10

Oxacillin, hepatic dysfunction (ab) 150; induced nephritis (ab) 447

P

Packaging of Medication, effect on patient compliance, 10

Parenteral Alimentation, adverse reactions (ab) 92; pharmacist's role in monitoring, 576

Parkinson's Disease, drug-induced symptoms, 166

Partition Coefficient and Diffusion of Drugs, 470

Pathocil, See **Dicloxacillin**

Patient
ambulatory, attitude toward pharmacy service, 710
compliance studies, 10
instructing the diabetic, 422
instructions for amoxicillin, 545
medication errors by, 430

Patient Teaching Program, 374

Pearson, Robert E. (author) **Evaluation of Amoxicillin**, 542

Pedameth, See **dL-Methionine**

Pediatric Case Study, cystic fibrosis, 58

Pelcor, Francis R. (author) book review, 398

Pen A/N, See **Ampicillin**

Penbritin, See **Ampicillin**

Penicillin, intralipid stability, 75

Penthrane, See **Methoxyflurane**

Perhexiline Maleate, angina treatment (ab) 94

Ferry, Paul J. (co-author) **Family Practitioner - Clinical Pharmacist Group Practice**, 572

Persantine, See **Dipyridamole**

Peterson, Robert V. (author) book review, 195

Peyote, in alcoholism (ab) 717

Pharmacists, evaluation as consultant, 242

Pharmacist's Role
ambulatory roles, limitations, 715
community pharmacy, 85
in cystic fibrosis, 58
in emergency care, 392
in instructing diabetic patient, 422
in instructing patient, 10
as patient instructor, 374
in preventing medication errors, 430
in reducing drug costs, 108
as therapist (ab) 201

Pharmacists, attitude toward clinical pharmacy, 238

Pharmacokinetics, See also **Biopharmaceutics**

amphetamine (ab) 205; **Considerations in Clinical Drug Trials**, 222, letter commenting on articles, 556; **cefazolin** (ab) 253; **cephaloridine** (ab) 253; **cephalothin** (ab) 253; **cromolyn**, 21; **digoxin** (ab) 150, 644; **diphenylhydantoin**, 462; **furosemide** (ab) 410; **doxycycline** (ab) 678; **drug distribution in pyelonephritis**, 512; **gentamicin** (ab) 43, 494, 650; **kanamycin**, 42, 228; **minocycline**, 71; **phenetermine** (ab) 205; **phenylbutazone** half life (ab) 410; **plasma levels and pharmacological effect**, 528; **practolol** (ab) 253; **ticarcillin** (ab) 95; **tobramycin** (ab) 497; **warfarin** (ab) 254

Pharmacology, and clinical pharmacy (ab) 201; **role of** (ab) 201

Pharmacy, community practice, 65; and the public, 65; separate from drugstores, 65; specialization in (ed) 105, (letters) 400, 405

Pharmacy Service, attitude of physicians and nurses toward 24-hour, 231; **compounding and consulting**, 242; **interaction of patient-physician-pharmacist in clinic**, 573

Pharmacy in the Soviet Union, (ed) 688

Pharmacy Technicians, need for in outpatient pharmacies, 710; **report of study** (letters) 143; **See also Pharmacy Technologists**

Pharmacy Technologist (ed) 421, (letters) 720, 559; and clinical pharmacist, 614, 669

Phenacetin, **Metabolism**, effect of cigarette smoking (ab) 206

Phenobarbital, effect on hyperlipemia (ab) 93; in seizure disorders, 581

Phenothiazines, **Extrapyramidal Reactions**, 166; letter commenting on, 444

Phentermine, bioavailability and pharmacokinetics (ab) 205

Phenylbutazone, half-life in impaired liver function (ab) 410; **interaction with tolbutamide** (ab) 203; **interaction with tolbutamide** (ab) 494

Phenylephrine, **interaction with debrisoquine** (ab) 408

Phenytoin, **choreo-athetosis and encephalopathy from** (ab) 676; **See also Diphenylhydantoin**

Phillips, D. J. (co-author) letter concerning drug expense comparison, 403

Physicians, attitude toward twenty-four hour clinical pharmacy service, 231; **power and influence** (ab) 718; **prescribing habits**, 81, 89

Physostigmine, **amitriptyline overdose** (letters) 144

Piccoro, John J. (co-author) **The Value of Emergency Care Situations in the Clinical Education of a Pharmacist**, 392

Pietrusko, Robert G. (author) letter concerning physostigmine in amitriptyline overdose, 144; (co-author) **Drug Expense Comparison—Traditional Distribution System vs. Decentralized Unit Dose**, 178

Pluhar, Robert E. (author) book review, 666

Podophyllum Resin, **teratogenic effects**, 691

Polyclillin, See **Ampicillin**

Porter, L. Kent (author) **Digitalis Toxicity**, 700

Potassium, **metabolism in elderly**, 476

Potassium Penicillin G, **adverse reactions** (ab) 92

Potassium Permanganate, **pyloric stenosis** (ab) 204

Powell, J. Robert (co-author) **Pharmacist's Role in Monitoring Total Parenteral Nutrition**, 576

Practolol, **pharmacodynamics in renal failure** (ab) 253

Prazosin, **new antihypertensive agent** (ab) 678

Pregnancy, **smoking in** (ab) 246

Presamine, See **Imipramine**

Prescription Proprietaries Guide (Letters) 720

Prescriptions, **accuracy in compounding**, 242; **mail-order** (ab) 405

Primidone, in seizure disorders, 581; **teratology**, 690

Principen, See **Ampicillin**

Procainamide, **fever, vomiting, liver dysfunction from** (ab) 676; **plasma concentration and exertional arrhythmias** (ab) 549; **overdose** (ab) 145

Prochlorperazine, **adverse reactions**, 166

Proctor, Rita K. (author) **Cromolyn Sodium**, **evaluation**, 20

Product Selection, **comment on antisubstitution laws** (letters) 402

Profits, **relationship of dosage form, therapeutic class and pharmacy service on drug costs**, 719

Pronestyl, See **Procainamide**

Propicillin, **combination with dicloxacillin for pseudomonas aeruginosa infections** (ab) 39

Propoxyphene, **poisoning** (ab) 676

Propranolol
adverse drug reactions (ab) 42; **adverse reactions** (ab) 93; **in angina pectoris**, 382; **digitoxin toxicity**, 706; **sinus arrest** (ab) 146; **therapy in action tremors** (ab) 449

Prostaphlin, See **Oxacillin**

Prostatic Fluid, **diffusion of drugs into**, 470; (letters) 667, 668

Psychotherapeutic Agents, **CNS, antidepressants**, 591; **drug interactions**, 591

Public Health, **pathogens in water containing ornamental fish** (ab) 720, **viruses from soiled diapers** (ab) 718

Parinethol, See **Mercaptopurine**

Pyelonephritis, **antibiotic therapy**, 512

Q

Quelcin, See **Succinylcholine**

Questran, See **Cholestyramine**

Quinidine, **adverse drug reactions** (ab) 41

R

Rapp, Robert P. (co-author) **The Value of Emergency Care Situations in the Clinical Education of a Pharmacist**, 392

Ravenscroft, F. J. (co-author) letter concerning drug interactions with thiethylperazine, 558

Reamy, Ralph D. (author) letter concerning mineral content of hyperalimentation solution, 34

References for 1974, 731

Rehder, Terry L. (author) abstracts, 41, 42, 92, 94, 447

Renal Failure, **diphenylhydantoin dosing**, 462

Renal Function, and **digoxin malabsorption**, 644

Renal Levels, of **antibiotics**, 512

Research
attitudes of ambulatory patients, 710
attitudes of pharmacists toward clinical pharmacy, 238
attitudes of physicians and nurses toward 24-hour pharmacy service, 231
drug evaluation, 528, 531
pharmacist as compounding and consultant, 242

Rezamycin, See **Tetracycline**

Rifadin, See **Rifampicin**

Rifampicin, **acute renal failure** (ab) 548; **adverse drug reaction** (ab) 494; **hepatorenal failure** (ab) 548

Rimactane, See **Rifampicin**

Ritalin, See **Methylphenidate**

Ritschel, W. A. (author) book review, 398

RO 10-8756, 542

Robitet, See **Tetracycline**

Rodowkas, Christopher A., Jr. (co-author) **The Development and Testing of a Methodology to Measure the Attitudes of Pharmacists Toward Clinical Pharmacy**, 238

Romanikiewicz, John A. (author) **Factors Influencing Renal Distribution of Antibiotics in Pyelonephritis Therapy**, 512

Rose, Beverly S. (author) **See Suffness and Rose**, 694

Rowles, Brandt (co-author) **The Pharmacist as Compounding and Consultant**, 242

RRL 2333, 542

Rubella Vaccine, **teratogenic potential**, 691

Rubino, Mark J. (co-author) letter concerning trimethoprim-sulfamethoxazole in prostatitis, 668

Russia, **Pharmacy in**, 688

S

Salicylates, **adverse effects**, 695; **drug interactions**, 145; **infant salicylism**, 495

Sansert, See **Methysergide maleate**

Schulze, Bernd W. (author) **Myasthenia Gravis**, **Clinical Pharmacy Study**, 255; **letter correcting myasthenia gravis article**, 445

Schwartz, Michael A. (author) **Approaching the Future of Community Pharmacy**, 65

Schwerman, Earl (author) **response to letter concerning medicines for cardiorespiratory arrest**, 32

Sedatives, **H.S. Sedation** (letters) 250, 493

Seitz, J. A. (co-author) letter concerning Hays letter on drug bioavailability, 559

Seizure Disorders, **drug therapy**, 581

Scherke, Joseph (co-author) **Drug Interactions Involving the Drugs of Abuse**, 120

Shearer, Cameron A. (author) abstracts, 617, 675, 677, 678, 723, 724, 725

Shimomura, Sam K. (co-author) **The DIAS Rounds**, 437

Siler, W. A. (author) letter concerning brand interchange, 402

Silver Sulfadiazine, **in vitro antibacterial activity** (ab) 93

Silverman, Harold M. (author) **Fetal and Newborn Adverse Drug Reactions**, 690

Silverman, Steve (co-author) letter concerning Dilantin piggybacks, 491

Sinequan, See **Doxepin**

Skin Infections, **drug therapy**, 535

Skinner, William J. (author) letter concerning clinical pharmacy education, 74

Smith, Dorothy L. (author) letter correcting error in **Perspectives in Clinical Pharmacy**, 71

Smith, Joe E. (co-author) **Drug Expense Comparison—Traditional Distribution System vs. Decentralized Unit Dose**, 178; **letter concerning drug expense comparison**, 403

Smoking in Pregnancy (ab) 246

Social Studies in Pharmacy

attitudes of patients, ambulatory toward pharmacy service, 710; attitudes of pharmacists toward clinical pharmacy, 238; attitudes of physicians and nurses toward 24-hour clinical pharmacy service, 231

Sodium Cyanate, for sickle-cell disease (ab) 254

Sodium Nitroferrocyanide, See Sodium Nitroprusside

Sodium Nitroprusside, in ergotamine-induced peripheral ischemia (ab) 206

Sorkness, Ronald (co-author) letter concerning trimethoprim-sulfamethoxazole in prostatitis, 668

Soviet Union, community pharmacy in (ed) 688

Specialization in Pharmacy (ed) 105; (letters) 400; (letters) 445

Spencer, Edward (author) The Attitudes of Ambulatory Patients Toward a Hospital-Based Pharmacy Service: The Patient as a Consultant, 710

Sperandio, G. J. (co-author) Clinical Pharmacy Activities in a VA Hospital, 656

Stability, Intralipid-Penicillins, 75; vancomycin, 520

Staphicillin, See Methicillin

Sterility of Screw Capped Bottle Systems, 74

Steroids, fluorinated, adverse reaction (ab) 548

Streptokinase, for pulmonary embolism (ab) 498

Streptomycin, synergism with vancomycin against enterococci (ab) 41

Substitution Laws, comment (letters) 402

Succinylcholine, apnea (ab) 146

Sucostrin, See Succinylcholine

Suffness, Matthew (author) Potential Drug Interactions and Adverse Effects Related to Aspirin, 694

Sulfasoxazole-Trimethoprim, prostatic fluid (letters) 667, 668

Sumycin, See Tetracycline

Supen, See Ampicillin

Supportive Personnel in Pharmacy (ed) 421

Supreme Court, reversal of Liggett Decision (ed) 7; reversal of Liggett decision, 27

Swintowsky, Joseph V. (co-author) The Value of Emergency Care Situations in the Clinical Education of a Pharmacist, 392

Sympathomimetic Amines, interactions, 591, untoward effects of (ab) 496

Synthroid, See Thyroxine

T

Talwin, See Pentazocine

Tangrea, Joseph A. (co-author) Investigational Drug Information, 182; Investigational Drug Information, bradykinin, 25

Teaching, drug self-administration, 374

Technologist, assistant for clinical pharmacist (ed) 421

Technology Assessment, and the report from the Drug Bioequivalence Study Panel (ed) 461

Tegretol, See Carbamazepine

Teratology, adverse drug reactions, 690

Tetracycline, excretion with altered urinary pH (ab) 205, hepatotoxicity (ab) 448

Tetracycline, See Tetracycline

Thayer, Charles F. (author) book reviews, 489

Theophylline, concentration in plasma and saliva (ab) 615

Thiethylperazine-Aminophyllin, incompatibility, 721 (letter)

Thioctan, See Thioctic Acid

Thioctic Acid, availability (letter) 614

Thioridazine, pigmentary retinopathy (ab) 42

Thomas, Jack (author) Letter regarding Australasian drug information sources, 720

Thyrotropin Releasing Hormone, investigational drug information, 663

Thyroxine, action in methadone and heroin addicts (ab) 410; L-thyroxine, in hypothyroidism (ab) 411

Ticarcillin, clinical pharmacology of (ab) 95

Tobias, Dianne E. (co-author) Suspected Digoxin Malabsorption, 644

Tobramycin, pharmacokinetics (ab) 43; serum levels (ab) 497

Tofranil, See Imipramine

Tolbutamide, interaction with phenylbutamide (ab) 203

Toin Unicelles, See Diphenylhydantoin

Tong, Theodore G. (co-author) letter concerning H. S. Sedation, 493; (co-author) letter concerning trimethoprim diffusion into prostatic fluid, 667

Torecan, See Thiethylperazine

Trantoin, See Nitrofurantoin

Trescillin, See Propicillin

Tricyclic Antidepressants, interactions, 591; teratogenic effects, 691

Trimethoprim, prostatic fluid (letters) 667, 668

Turner, Paul (author) Principles of Experimental Design for Producing Solid Data in Clinical Trials, 528

Tyramine Content of Food, 591

Tyramine, investigational drug, 182

Tyrosamine, investigational drug, 182

U

Ultrapen, See Propicillin

Unit Dose, savings from, 178

V

Valium, See Diazepam

Vancocin, See Vancomycin

Vancomycin, review of use, 520; synergism with gentamicin against enterococci (ab) 41; stability, 521; biopharmaceutics, 521

Van Slyke, Robert E. (author) letter concerning specialization in pharmacy, 445

Varano, Carmine (author) letter regarding editorial, on accepting things as they are, 492, (author) letter regarding new goals for the ASHP, 721

Vasopressin-resistant diabetes from demeclocycline (ab) 41

Veracillin, See Dicloxacillin

Veterans Administration, clinical pharmacy activities, 656

Vibramycin, See Doxycycline

Vincristine, neurotoxicity (ab) 548

Vinyl Chloride, liver angiosarcoma from (ab) 547

Viruses, soiled diapers as source (ab) 718

Vitamin D, neonatal tetany, 692

Vitamin U, See L-Methylmethionin Sulfonion Chloride

W

Walizer, Donald (co-author) Attitudes of Physicians and Nurses Exposed to Pharmacists Providing Twenty-four Hour Service in the Satellite Pharmacy of a Medical Center, 231

Warfarin dose index, 138; half life, 138; interaction with mercaptopurine (ab) 616; kinetics of absorption (ab) 254

Weinstein, William M. (author) letter concerning repeal of ant substitution laws, 142

Weissman, Fred G. (author) Bacterial Infection of the Skin and Considerations in Drug Therapy, 535

Whitney, Harvey A. K., Jr. (ed) New Goals for the ASHP: Opportunity Knocks Only Once! 511; The Pharmacy Technologist: A New Assistant for the Clinical Pharmacist, 421; (author) book review, 490, 665

Winship, Henry W., III (co-author) The Pharmacist's Role in Preventing Medication Errors, 430

Witt, L. D. (co-author) letter concerning H.S. sedation, 493; (co-author) letter concerning trimethoprim diffusion into prostatic fluid, 667

Wood, Warren (author) abstracts, 411

X-Y-Z

Xylocaine, See Lidocaine

Yeh, Tobias (co-author) letter concerning H.S. Sedation, 493

ADVERTISERS

Abbott Laboratories
Abbo-Pac®, unit dose, S-508-509, O-568-569, N-628-629, D-686-687

American Institute of the History of Pharmacy
Membership Information, F-77, Mr-148, Ap-199, Ju-407, Ag-460, S-504, N-679

American Society of Hospital Pharmacists
International Pharmaceutical Abstracts, Mr-102, Ma-ibc; Research & Education Foundation, Drugs in Health Care, Ap-171

Australasian Drug Information Services Pty Ltd.
Editorial Staff position open, Ja-33

Brooklyn College of Pharmacy
Assistant Professor of Clinical Pharmacy, two positions, D-732

Paul de Haen, Inc.
De Haen Drugs in Research, Ju-ibc, Jl-ibc

Dow Pharmaceuticals
"To know us better is to trust us more," Mr-99, Ma-212

Drug Intelligence & Clinical Pharmacy, Inc.
Subscription Information, each month, ifc

Drug Intelligence Publications, Inc.
Books and Tapes available, Ju-368-371, Jl-

416-419, Ag-456-459, S-550-555, O-608-611, N-670-674, D-726-729

Principles of Clinical Pharmacy Illustrated by Case Studies, Jl-450, S-554, O-619, N-674, D-683

DI Audio Courses, Ja-36, 37, F-72-73, Mr-100-101, Ap-196, 197, 200, Ma-216-219, Ju-368-371, Jl-416-419, Ag-456-459, S-550-555, O-608-611, N-670-674, D-726-730

Fundamentals of Medications, 2nd Ed., Ap-207, Jl-451, Ag-498, S-ibc, N-ibc, D-ibc

Handbook of Clinical Drug Data, Ja-6, F-76, Mr-149, Ap-159, Ma-220

Handbook of Drug Interactions, Ja-38

Index Nominum, Ja-5, Ap-158

IV Additive Reviews, Ap-157, S-505, O-607, N-643, D-730

Publications available, Ja-ibc, F-ibc, Mr-ibc, Ap-ibc

Ritschel's Biopharmaceutics Lab Manual, Ag-499, O-620

Social and Economic Aspects of Drug Utilization Research, Ja-40, F-80, Mr-151

Geigy Pharmaceuticals
DBI-TD®, Ja-3, F-51, Mr-103

InPHARMATION, Ma-215

Insti p for Scientific Information
Is keeping up getting you down? Ju-397, Jl-420

S. Karger
Pharmacology and the Future of Man, Ju-404

Eli Lilly and Co.
Davron® Compound-65, Ma-obc, Ju-obc
Davron® Compound-65 and Darvocet-N® 100, Jl-obc, Ag-ibc, N-626

Keflex®, It makes sense, F-obc, Mr-obc, O-ibc

Keflin® I.V., Ja-obc, Ap-obc, S-503, D-obc

McGraw Laboratories
The ADDIT IV® System, Ju-367, Jl-415

FreAmine, Mr-118, 119; Ma-214, 215

FreAmine II, S-506-507, O-566-567

McGraw Is Responsive, Ap-160-161

Shock! and Seconds, N-624, 625

Merrell-National Laboratories
Bentyl®, Ag-obc, S-obc, O-obc, N-obc

Millipore Corporation
AM 303, N-627

Millex #1 "Think," N-623

Plenum Publishing Corporation
Journal of Pharmacokinetics and Biopharmaceutics, Ja-4, F-79, Mr-147

The Professional Data Services Center, Inc.
Computerized Data Base, Ja-19, Mr-117, O-617

Rachelle Laboratories, Inc.
Doxychel, F-54, Ap-162

Hospital Pharmacy Bookshelf Selections, Winter 1974, Ja-35

Roche Laboratories
Catalysts, The Roche Hospital Pharmacy Advisory Board, S-526-527, N-648-649

Dalmane®, F-52-53

The 1974 Roche Hospital Pharmacy Research Grant Program, Mr-104, Ap-156

The 1973 Winners of the Roche Hospital Pharmacy Research Grant Program, O-588-589, D-684-685

St. Jude Children's Research Hospital
Helping Children, Ag-482, O-567

Smith Kline & French Laboratories
Ancef®, Ja-8, 9; F-56, 57; Mr-106, 107, Ap-164, 165

Now 10 Products, Ap-155, Ma-213, Ju-372, S-510

Single Unit Packages, O-570, N-630

E. R. Squibb & Sons
Velosef®, O-564, 565

When the choice is yours . . . , Ma-211, Ag-455, O-563

State University of New York, Buffalo
Position Available, F-98; Ag-500

University of Alberta
Graduate Programs Available, F-96

University of California San Francisco
Announcement of Residencies, N-625, D-709

University of Cincinnati
Residencies in Clinical Pharmacy D-716

University of Connecticut
Assistant Clinical Professor, O-618

University of Connecticut Health Center
Pharmacy Residency Available, Mr-144

University of Manitoba
Pharmacy Faculty Associate Professor, Ju-412

University of Southern California
Clinical Pharmacy Residencies, Ja-43, F-95

Faculty Position, Ag-500, S-560

University of Washington
Chairperson, Department of Pharmacy Practice, Jl-452

